Orgenesis Inc., a global biotech company working to unlock the full potential of cell and gene therapies, and Koligo Therapeutics Inc., a regenerative medicine company, have entered into a definitive merger agreement, subject to final closing conditions, with expected completion before year-end.     Koligo specializes in developing personalized cell therapies utilizing the patient’s own (autologous) cells. Koligo has successfully launched its first commercial product, KYSLECEL, and plans to comm...